FDA Commissioner Marty Makary was met with a skeptical set of Senate appropriators Thursday when he testified on his agency’s ...

As the FDA prepares for a busy Oncologic Drugs Advisory Committee meeting next week, an agency insider told BioSpace that ...

Pfizer faces several headwinds, including patent cliffs, regulatory risks, and a setback in obesity drug development. Click ...

The U.S. Food and Drug Administration on Tuesday said it plans to require new clinical trials for approval of annual COVID-19 ...

The labelling puts it in direct contention with Pfizer's ... include pursuing regulatory approvals outside the US, starting with Europe – where it has already filed the drug, with a decision ...

The U.S. FDA approved Novavax's COVID-19 vaccine with conditions, allowing use for people 65 and older and those 12-64 with ...

The U.S. FDA has approved Novavax's COVID-19 vaccine, Nuvaxovid, for older adults and those aged 12 to 64 at risk of severe illness. Despite missed deadlines and regulatory challenges, the approval is ...

These 26 stocks are working on everything from early diagnostics to drug discovery ... uncertainties in regulatory outcomes and market acceptance. Despite these factors, Pfizer's share price ...

U.S. regulators will no longer approve COVID booster shots for healthy adults and children without new studies, adding a ...

The Global Nanomedicine Market is expected to witness a growth rate of 10-12% in the next five years. Ongoing research and ...

IntroductionThe global vaccines market has witnessed unprecedented growth in recent years, driven by technological ...